Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
LTM Revenue ($mm)
LTM Date
Source
Abcam, Inc.
51.80
-
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Abcam, Inc. manufactures, markets, and distributes antibodies. The company was incorporated in 2003 and is based in Cambridge, Massachusetts. Abcam, Inc. operates as the subsidiary of Abcam Ltd.
Akzo Nobel N.V. (ENXTAM:AKZA)
11,446.33
Jun-30-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Akzo Nobel N.V. engages in the production and sale of paints and coatings worldwide. It offers decorative paints, including paints, lacquers, and varnishes; and a range of mixing machines and color concepts for the building and renovation industry, as well as specialty coatings. The company also provides performance coatings that protect and enhance ships, cars, aircraft, yachts, architectural components, consumer goods, and oil and gas facilities. It offers its products primarily under AkzoNobel, Alabastine, Alba, Andercol, Apla, Armstead Trade, Astral, AwlGrip, Dulux, Bruguer, Cetabever, Cetol, Chemcraft, Colourland Paints, Coral, Cromadex, Cuprinol, Dynacoat, Flexa, Glitsa, Grip-Gard, Zweihorn, Xylazel, Xyladecor, Wanda, Vpowdertech, Vivechrom, U-tech, Trimetal, Titanlux, Taubmans, Sparlack, Sikkens, Savana, and Salcomix, as well as Sadolin, Resicoat, Relest, Procolor, Polyfilla, Polycell, Pinotex, Pintuco, Oxirite, Nordsjo, Molto, Modern Classikk, Maxilite, Mauvilac, Mason CT, Marshall, Laxol, Levis, Lesonal, Interpon, International, Interlux, Innenweis, Inca, Herbol, and Hammerite brands. The company was formerly known as Akzo NV and changed its name to Akzo Nobel N.V. in 1994. Akzo Nobel N.V. was founded in 1646 and is headquartered in Amsterdam, the Netherlands.
Alexion Pharmaceuticals, Inc.
6,261.60
Mar-31-2021
Lonza Group AG (SWX:LONN) - Form 
Business Description: Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma sebelipase alfa for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 Intravenous, which is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 Subcutaneous, which is in Phase III clinical trials for PNH and aHUS; ALXN1820 which is in a Phase I clinical trial as a therapeutic antagonist of properdin; and ALXN1720, which is in a Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840, which is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which is in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for the treatment of relapsed/refractory chronic lymphocytic leukemia. It serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has a collaboration and license agreement with Neurimmune AG, Dicerna, Merck, and Zealand Pharma. The company was incorporated in 1992 and is based in Boston, Massachusetts, with an additional office in Zürich, Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Almac Group Limited
987.27
-
Codexis, Inc. (NasdaqGS:CDXS) 2022 Form 10-K
Business Description: Almac Group Limited provides integrated services for companies in pharmaceutical and biotechnology sectors in the United Kingdom and internationally. The company offers biomarker discovery and development solutions, such as biomarker services, companion diagnostic development, biomarker clinical trial management, internal biomarker discovery, proprietary discovery arrays, genomic services, bioinformatics consulting, and formalin fixed paraffin embedded solutions; active pharmaceutical ingredient (API) services and chemical development solutions, including API development and manufacture, peptide and protein technology, solid state services, analytical, isotope chemistry, biocatalysis, FLEXYTE fluorescence lifetime assays, and animal free chemokines; and pharmaceutical development services, such as preformulation, non-GMP pharmaceutical development, early stage development, scale up and late stage development, clinical trial manufacture, contained development and manufacture, and analytical services. It also offers analytical services, including physical and chemical characterization, method development and validation, Active Pharmaceutical Ingredients (API) and drug product testing, stability testing, impurity identification and structure elucidation, and bioanalytical services; clinical trial supply chain solutions, such as clinical trial manufacture, comparator sourcing and blinding, packaging and labeling, distribution and supply chain management, QP services, clinical supply consulting, and integrated IVR/IWR solutions; clinical technology solutions; and other commercial services that range from manufacturing, testing, and packaging to end-user distribution. Almac Group Limited has a strategic partnership with Personal Genome Diagnostics Inc. Almac Group Limited was formerly known as Almac Sciences Group Limited and changed its name to Almac Group Limited in November 2005. Almac Group Limited was incorporated in 2001 and is based in Craigavon, United Kingdom. It has operations in the United Kingdom; Pennsylvania, North Carolina, and California, the United States; and Singapore, Ireland, United States of America, and Tokyo.
Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH)
540.89
Jun-30-2023
Lannett Company, Inc. 2019 Form 10-K
Business Description: Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP)
401.39
Jun-30-2023
Lannett Company, Inc. 2019 Form 10-K
Business Description: ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Arkema Inc.
1,244.98
-
Lonza Group AG (SWX:LONN) - Form 
Business Description: Arkema Inc. manufactures and retails diversified chemicals. It offers industrial chemicals, including acrylic monomers, emulsion systems, fluorochemicals, fluoropolymers, functional additives, hydrogen peroxide, PMMA, specialty polyamides, and thiochemicals; coating solutions, such as acrylics and coating resins and additives; and high-performance materials, which include specialty adhesives, technical polymers, and performance additives. The company caters to  air conditioning, automotive and transportation, consumer goods, food and agrochemicals, as well as paints, coatings, and adhesives markets worldwide. Arkema Inc. was formerly known as Atofina Chemicals, Inc. and changed its name to Arkema Inc. in October 2004. The company was incorporated in 1850 and is based in King of Prussia, Pennsylvania. Arkema Inc. operates as a subsidiary of Arkema S.A.
Assertio Holdings, Inc. (NasdaqCM:ASRT)
168.02
Jun-30-2023
Lannett Company, Inc. 2019 Form 10-K
Business Description: Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
BASF Corporation
4,164.38
-
Lonza Group AG (SWX:LONN) - Form 
Business Description: BASF Corporation manufactures and supplies basic chemicals and intermediates ranging from solvents, plasticizers, and monomers to glues and electronic chemicals, as well as raw materials for detergents, plastics, textile fibers, paints and coatings, plant protection, and pharmaceuticals. The company also provides petrochemicals, monomers, and intermediates; vitamins and food additives, as well as ingredients for pharmaceuticals, hygiene, home, and personal care; other products for the paper industry, oil and gas production, mining, and water treatment; and dispersion and pigments, care chemicals, nutrition and health products, paper chemicals, and performance chemicals. Also, it offers functional materials and solutions, such as catalysts, battery materials, engineering plastics, polyurethane systems, automotive and industrial coatings, concrete admixtures, and construction systems; and performance materials for automotive, electrical, chemical, and construction industries, as well as for household applications, and sports and leisure. Further, the company engages in the exploration and production of oil and gas. Furthermore, it offers WorldAccount, a web-based transaction and information platform; and analytics, eco-efficiency analysis, and technical services. It serves industries, such as aerospace, agriculture, automotive, chemicals, computer and electronics, construction, electrical equipment, feed, food and beverage, furniture, home, leather and apparel, machinery, mining, miscellaneous manufacturing, nonmetallic mineral products, oil processing, packaging, personal care, pharmaceutical, plastics product manufacturing, primary metal, printing and graphics, pulp and paper, rubber, textiles, transportation, utilities, wind energy, and wood. It has a strategic relationship with American Superconductor Corporation. The company was founded in 1865 and is based in Florham Park, New Jersey. BASF Corporation operates as a subsidiary of BASF SE.
Biogen Inc. (NasdaqGS:BIIB)
9,971.50
Jun-30-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Catalent, Inc. (NYSE:CTLT)
4,276.00
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Charles River Laboratories International, Inc. (NYSE:CRL)
4,178.31
Jul-01-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Codexis, Inc. (NasdaqGS:CDXS)
99.15
Jun-30-2023
Codexis, Inc. (NasdaqGS:CDXS) 2022 Form 10-K
Business Description: Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company’s platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Covidien plc (Acquired)
10,643.00
Dec-26-2014
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: As of January 26, 2015, Covidien plc was acquired by Medtronic plc. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company operates through Medical Devices and U.S. Medical Supplies segments. It sells advanced surgical solutions comprising stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and ablation products, and interventional lung and gastrointestinal solutions, as well as general surgical solutions, including surgical instruments, sutures, and electrosurgery products; and peripheral vascular therapies, such as compression, dialysis, venous insufficiency, peripheral stents, directional artherectomy, and other products, as well as neurovascular therapies comprising coils, neurovascular stents, flow diversion products, and access and delivery products to support procedures. The company also offers patient monitoring products, such as sensors, monitors, and temperature management products; airway and ventilation products, including airway, ventilator, and inhalation therapy products, as well as breathing systems; and nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products. In addition, it sells patient care products, such as operating room supply products and electrodes; original equipment manufacturer products; and SharpSafety products comprising needles, syringes, and sharps disposal products. The company’s products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. It markets its products through direct sales force and third-party distributors. The company was founded in 2007 and is based in Dublin, Ireland.
Curia Global, Inc.
680.82
Jun-30-2017
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Curia Global, Inc. operates as a contract research, development, and manufacturing organization. The company discovers and develops an active pharmaceutical ingredient (API); and develops a messenger RNA (mRNA) solution to streamline the development and delivery of mRNA-based products. It offers custom API manufacturing, fermentation, finished dosage form, high potency, lipid nanoparticle, rare/orphan, stability and release testing, sterile fill finish, APIs and intermediates catalog, and fine chemicals catalog. The company offers analytical testing services, batch release and stability lot testing, extractables and leachable, method development and validation, package and device testing, and solid-state chemistry lab testing services. It also offers intellectual property litigation support, intellectual property services, regulatory support, quality assurance, and sterile university consultative services. The company offers products and services from research and development through commercial manufacturing to pharmaceutical and biopharmaceutical customers. The company was formerly known as AMRI and changed its name to Curia Global, Inc. in July 2021. Curia Global, Inc. was founded in 1991 and is headquartered in Albany, New York.
Dr. Reddy's Laboratories Limited (BSE:500124)
3,135.23
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Eurofins Scientific SE (ENXTPA:ERF)
6,857.79
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Evotec SE (XTRA:EVT)
841.05
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Francopia S.A.R.L.
86.72
-
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: Francopia S.A.R.L. operates as a subsidiary of Sanofi.
Genentech, Inc.
13,418.00
Dec-31-2008
Lonza Group AG (SWX:LONN) - Form 
Business Description: Genentech, Inc. operates as a biotechnology company that discovers and develops medicines for people with diseases. It offers medicines for the areas of oncology, immunology, neuroscience, metabolism, infectious disease, and ophthalmology. The company was formerly known as Genentech Delaware, Inc. and changed its name to Genentech, Inc. in January 1987. The company was founded in 1976 and is based in South San Francisco, California with additional offices in Hillsboro,Oregon; Vacaville and Oceanside, California. Genentech, Inc. operates as a subsidiary of Roche Holding AG.
ICON Public Limited Company (NasdaqGS:ICLR)
7,903.26
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Illumina, Inc. (NasdaqGS:ILMN)
4,461.00
Jul-02-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
IQVIA Holdings Inc. (NYSE:IQV)
14,681.00
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
Johnson Matthey Plc (LSE:JMAT)
18,141.73
Mar-31-2023
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: Johnson Matthey Plc engages in the clean air, catalyst and hydrogen technology, and platinum group metals (PGM) service businesses in the United Kingdom, Germany, rest of Europe, the United States, rest of North America, China, rest of Asia, and internationally. It operates through five segments: Clean Air, PGM Services, Catalyst Technologies, Hydrogen Technologies, and Value Businesses. The Clean Air segment provides catalysts for emission control after-treatment systems to reduce harmful emissions from cars, other light duty vehicles, trucks, buses, and non-road equipment powered by internal combustion engines. The PGM Services segment enables the energy transition through providing circular solutions as demand for critical materials. This segment also offers PGM refining and recycling, and trading services; other precious metal products; and PGM chemicals, industrial products, and catalysts. The Catalyst Technologies segment is involved in decarbonization of chemical and fuel value chains. This segment also provides speciality catalysts and additives; process technology licenses; and engineering design services. The Hydrogen Technologies segment offers catalyst coated membranes that are a critical component for fuel cells and electrolysers. The Value Businesses segment business portfolio includes precious metal pastes and enamels, and battery systems and products for devices used in medical procedures; and detection and measurement solutions. The company was formerly known as Johnson & Cock and changed its name to Johnson Matthey Plc in 1851. Johnson Matthey Plc was founded in 1817 and is based in London, the United Kingdom.
K+S Aktiengesellschaft (XTRA:SDF)
5,237.75
Jun-30-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: K+S Aktiengesellschaft, together with its subsidiaries, operates as a supplier of mineral products for the agricultural, industrial, consumer, and community segments worldwide. It offers potassium chloride for crops, such as grain, corn, rice, and soybean; fertilizer specialties that are used for crops with magnesium and sulfur requirements, including rapeseed or potatoes, as well as for chloride-sensitive crops consisting of citrus, grapes, or vegetables; and water-soluble fertilizers for use in fertigation under the KALISOP, KORN-KALI, ROLL-KALI, PATENTKALI, ESTA KIESERIT, MAGNESIA-KAINIT, SOLUMOP, SOLUSOP, SOLUCMS, SOLUMAP, SOLUMKP, EPSO TOP, EPSO MICROTOP, EPSO COMBITOP, EPSO PROFITOP, and EPSO BORTOP brand names. The company also provides potash, magnesium, and salt products for various industrial applications under the APISAL, AXAL, KASA, k-DRILL, NUTRIKS, REGENIT, and SOLSEL brand names. K+S Aktiengesellschaft was founded in 1889 and is headquartered in Kassel, Germany.
Labcorp Drug Development Inc.
2,521.00
Dec-31-2014
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Labcorp Drug Development Inc. offers contract research and drug development services. Its services include preclinical and clinical trials, clinical trial laboratory services, post-marketing solutions, chemical product testing, crop protection, medical device development, and data and technology services to the pharmaceutical, medical technology, crop protection, and chemical industries. It caters to pharmaceutical and biotechnology companies. The company is based in Burlington, North Carolina. Labcorp Drug Development Inc. operates as a subsidiary of Laboratory Corporation of America Holdings.
LANXESS Corporation
1,362.87
-
Lonza Group AG (SWX:LONN) - Form 
Business Description: LANXESS Corporation develops, manufactures, and markets chemical intermediates, additives, specialty chemicals, and plastics. It offers industrial intermediates, including aromatic compounds, amines, benzyl products, hydrofluoric acid, sulfuric acid, phthalic anhydride, maleic anhydride, hydrazine hydrate, trimethylol propane, hexandiol, adipic acid, phenylenediamines, amines, monophenols, bisphenols, mercaptobenzimidazols, olefins, accelerators, peptizing agents, and sodium mercaptobenzothiazole; additives, such as polymer and lubricant additives; urethane systems that include urethane prepolymers, low free prepolymers, ribbon flow systems, urethane curatives, and polyester polyols; inorganic pigments; and liquid purification technologies. The company also provides explosives; adhesives and sealants; leather; material protection products; rubber and colorant additives; and custom synthesis and manufacturing services, which include phosgene derivatives, triazole and triazol derivatives, reagents and building blocks, polymer additives and functional products, and ligands. It serves agriculture, polymers, pigments and dyes, paints, automobiles, tire, technical rubber goods, fuels, construction, coatings, plastics and paper, power generation, food, chemical and petrochemical, pharmaceuticals, electrical and electronics, metal processing, mining, machine construction, sports and consumer electronics, and water treatment industries. LANXESS Corporation has a strategic partnership with Standard Lithium Ltd. LANXESS Corporation was formerly known as Bayer Chemicals Corporation. The company was incorporated in 2004 and is based in Pittsburgh, Pennsylvania. It has manufacturing facilities in Germany, China, India, and USA. LANXESS Corporation operates as a subsidiary of LANXESS Aktiengesellschaft.
Life Technologies Corporation
3,842.31
Sep-30-2013
International Stem Cell Corporation (OTCPK:ISCO) 2007 Form 10KSB
Business Description: Life Technologies Corporation operates as a life sciences company. The company’s Research Consumables business group offers molecular and cell biology reagents, endpoint PCR, and other benchtop instruments and consumables, such as RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling and protein analysis, cell culture media used in research, stem cells and related tools, cellular imaging products, antibodies, and cell therapy related products. Its Genetic Analysis business group provides capillary electrophoresis (CE) instruments used for research applications and various CE consumables; real-time and digital qPCR instruments used in research applications; qPCR consumables and genomic assays; and sequencing systems and reagents for the SOLiD and Ion Torrent systems. The company’s Applied Sciences business group offers bioproduction, forensics, and animal health and food safety reagent kits; CE; and qPCR instruments that are used in applied markets applications; and medical sciences products consisting of molecular diagnostics products and services. Life Technologies Corporation also provides repair and maintenance services; and custom services, such as cell line development, custom media modification, and primers and custom assays development services. Its products offer research tools for genomics studies, proteomics studies, gene splicing, cellular analysis, and other research applications required by laboratories associated with universities, medical research centers, and government and other research institutions, as well as biotechnology, pharmaceutical, and chemical companies. The company was founded in 1987 and is headquartered in Carlsbad, California. Life Technologies Corporation operates as a subsidiary of Erie N2 UK Limited.
Lonza Group AG (SWX:LONN)
7,031.03
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
Medtronic plc (NYSE:MDT)
31,558.00
Jul-28-2023
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company’s Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company’s Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Noramco, Inc.
108.00
-
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: Noramco, Inc. develops and produces active pharmaceutical ingredients for generic and branded pharmaceutical companies. The company offers cannabinoids, antagonists for addiction treatment and abuse prevention, ADHD/stimulants, agonists, and intermediates. Its medicines are used to treat attention deficit hyperactivity disorder, pain, addiction, and abuse-deterrent formulations. The company also accelerates formulation projects; produces clinical supplies of APIs; and performs custom synthesis services for controlled substances. It sells its products through an online portal. Noramco, Inc. was founded in 1979 and is based in Wilmington, Delaware with additional locations in Athens, Georgia with affiliate sites in Switzerland, Belgium, Australia, and the United Kingdom.
Novozymes A/S (CPSE:NZYM B)
2,503.61
Jun-30-2023
Codexis, Inc. (NasdaqGS:CDXS) 2019 Form 10-K
Business Description: Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
PAREXEL International Corporation
2,117.60
Jun-30-2017
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Parexel International Corporation, a biopharmaceutical outsourcing company, provides clinical research and logistics, medical communications, consulting, and technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company offers clinical development, including translational medicine, early phase, phase II-III, phase IIIb/IV, biostatistics, clinical data management, clinical supply chain management, decentralized clinical trials, medical monitoring and consulting, medical writing, patient sensors, pharmacovigilance, and risk-based quality management (RBQM); outsourcing services, including functional services provider (FSP), strategic partnerships, and meeting management and logistics; consulting, including regulatory affairs consulting, clinical development strategy and planning, GxP compliance consulting, regulatory outsourcing, clinical trial regulatory services, market access and HEOR consulting, and commercial strategy (health advances); medical affairs, including the medical affairs company (TMAC), medical communications, and expanded access services; real-world evidence and late phase, including epidemiology, observational studies, and real-world data sciences; industry solutions, including pharma solutions and medical devices; and development phase solutions. Parexel International Corporation has strategic agreements with Microsoft Corporation; Synairgen plc; and CTC North GmbH & Co. KG. The company was incorporated in 1983 and is based in Newton, Massachusetts, with branches in Waltham and Billerica, Massachusetts and Uxbridge, United Kingdom. It has additional locations throughout the world.
Patheon N.V.
1,933.00
Apr-30-2017
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Patheon N.V. provides outsourced pharmaceutical development and manufacturing services in the Netherlands. The company operates through three segments: Drug Product Services, Pharmaceutical Development Services, and Drug Substance Services. It offers a range of active pharmaceutical ingredient and finished drug product services, including formulation development, as well as clinical and commercial-scale manufacturing, packaging, and lifecycle management. It caters its services to small molecule and large molecule biological drugs sectors. The company was formerly known as Patheon Holdings Coöperatief U.A. and changed its names to Patheon N.V. in June 2016. Patheon N.V. was incorporated in 2013 and is headquartered in Durham, North Carolina. Patheon N.V. operates as a subsidiary of Thermo Fisher Scientific (Panama) B.V.
Pharmaceutical Product Development, LLC
1,594.81
Sep-30-2011
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Pharmaceutical Product Development, LLC, a contract research organization, provides drug development, laboratory, and lifecycle management services to pharmaceutical, biotechnology, medical device, academic, and government organizations worldwide. It offers nonclinical pharmacology/toxicology development and chemistry, manufacturing, and controls consulting services; and clinical development services, which include project management, site intelligence and activation, clinical trial monitoring, data, and analytics platform, data management, biostatistics, pharmacovigilance, functional service, regulatory affairs, quality, and compliance, IVR/IWR system services, clinical supplies, and clinical trial capabilities. The company also provides post-approval studies and late-stage research services, such as early planning, medical communications, medical writing, late-stage research, research coordination center, registries and observational studies, real-world outcomes, risk management, and REMS; consulting services, which include product development, biosimilar development, adaptive trial design, pediatrics, rare diseases, cardiovascular outcomes, global quality and compliance, and medical devices; and technology products and services development, learning development and training, business process and change management, and global technology services. It has strategic alliances with NeoGenomics, Inc. and Harbour BioMed. Pharmaceutical Product Development, LLC was founded in 1985 and is based in Wilmington, North Carolina, with additional offices worldwide. Pharmaceutical Product Development, LLC operates as a subsidiary of Wildcat Acquisition Holdings (UK) Limited.
Piramal Enterprises Limited (BSE:500302)
854.58
Jun-30-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Piramal Enterprises Limited operates as a non-banking financial company in India. The company provides housing finance and other financing solutions, such as private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting to real estate sector; and funding solutions to infrastructure, renewable energy, roads, industrials, auto components, and other sectors. It also operates distressed asset investing platform that invests in equity and/or debt in assets; provides life insurance services, as well as engages in fund management, property leasing, and manpower services businesses. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is headquartered in Mumbai, India.
PRA Health Sciences, Inc.
3,333.43
Mar-31-2021
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments: clinical research and data solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late-phase services. It also provides strategic solutions, such as embedded functional services providers, staff augmentation, and custom-built development solutions, as well as commercialization services and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. This segment offers market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies and clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, the central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. The company was founded in 1976 and is based in Raleigh, North Carolina. PRA Health Sciences, Inc. operates as a subsidiary of ICON Public Limited Company.
Prestige Consumer Healthcare Inc. (NYSE:PBH)
1,129.98
Jun-30-2023
Lannett Company, Inc. 2019 Form 10-K
Business Description: Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Quest Diagnostics Incorporated (NYSE:DGX)
9,488.00
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Quotient Sciences Limited
94.15
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2020 Form 10-K
Business Description: Quotient Sciences Limited, a drug development and manufacturing accelerator, provides integrated programs and tailored services to pharmaceutical and biotechnology customers worldwide. The company offers candidate selection, early development, and late development integrated programs. It also offers formulation development, clinical trial manufacturing, commercial manufacturing, clinical pharmacology, drug development consulting, data sciences, drug substance, and bioanalysis services. Quotient Sciences Limited was formerly known as Quotient Clinical Ltd. and changed its name to Quotient Sciences Limited in November 2017. The company was founded in 2004 and is based in Nottingham, United Kingdom.
Rhodia S.A.
6,538.50
Jun-30-2011
Lonza Group AG (SWX:LONN) - Form 
Business Description: Rhodia SA, together with its subsidiaries, develops, produces, and markets specialty chemicals in the Asia Pacific, Europe, Latin America, and North America. The company produces Polyamide 6.6; intermediates and polymers for industrial paints, textiles, tires, airbags, automotives, and electronics; engineering plastics for automotive and transport, electrical, electronics, construction, industrial equipment, and consumer goods; textile yarn for lingerie, sportswear and beachwear, socks, and fashion; industrial yarn for tires, conveyor belts, sewing threads, ropes, and fishing nets; and staple fiber for abrasives, mixtures of fibers, and filtration markets. It also provides acetate tow and cellulose acetate flakes for the cigarette and textile industry; sulfuric acid, regeneration services, and sulfur derivatives for oil refining, and chemical and petrochemical production markets; energy management services and climate care solutions; and surfactants, polymers and monomers, phosphorus derivatives, and solvents for cosmetics, detergents, agrochemicals, lubricants, emulsions, industrial applications, and oil industries. In addition, the company offers phenol for resins and industrial goods, automotive, lumber, and construction markets; and oxygenated solvents for the industrial paints, leather, automotive, packaging, and inks markets. The company was founded in 1989 and is based in Paris, France. As of August 24, 2011, Rhodia SA operates as a subsidiary of Solvay SA.
Roche Holding AG (SWX:ROG)
70,256.92
Jun-30-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Shanghai SynTheAll Pharmaceutical Co., Ltd.
402.06
Mar-31-2019
Codexis, Inc. (NasdaqGS:CDXS) 2022 Form 10-K
Business Description: Shanghai SynTheAll Pharmaceutical Co., Ltd. provides services for the development and manufacture of active pharmaceutical ingredients (API). Its services range from preclinical to commercial development and manufacturing services for small molecule API and advanced intermediates to the life sciences community worldwide. The company offers services, such as early stage process development, such as synthetic route and process development; late stage process development, including commercial route development, commercial process development and optimization, and process validation/DOE/QbD; R&D manufacturing, such as pre-clinical and clinical batches manufacturing; and commercial manufacturing, including registration and commercial supplies. It also provides process analytical science services, such as analytical method development and validation; characterization, in process control, and release testing; impurity structure elucidation; and ICH stability studies. In addition, the company offers process engineering services, including crystallization process development, polymorph and salt screening, solid state characterization, process scale up, particle size control, and process safety evaluation; and project management services. Shanghai SynTheAll Pharmaceutical Co., Ltd. has a strategic partnership with Antengene Corporation. The company was founded in 2003 and is headquartered in Shanghai, China. Shanghai SynTheAll Pharmaceutical Co., Ltd. operates as a subsidiary of WuXi AppTec Co., Ltd.
Siegfried Holding AG (SWX:SFZN)
1,390.66
Jun-30-2023
Johnson Matthey Plc (LSE:JMAT) - Form Doc
Business Description: Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It also offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Sigma-Aldrich Corporation
2,781.00
Sep-30-2015
International Stem Cell Corporation (OTCPK:ISCO) 2007 Form 10KSB
Business Description: Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide. It offers products in the areas of analytical chemistry, cell culture and analysis, chemistry and biochemicals, clinical and diagnostics, filtration, industrial microbiology, labware, materials science, molecular biology and functional genomics, mRNA development and manufacturing, pharma and biopharma manufacturing, protein biology, and water purification. It offers media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing. The company also manufactures meglumine, an amino sugar derived from glucose and a component of medical imaging contrast media. It sells its products to pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies, non-profit organizations, governmental institutions, diagnostic, chemical and electronics companies, and hospitals. The company was founded in 1951 and is based in Burlington, Massachusetts with additional offices worldwide. Sigma-Aldrich Corporation operates as a subsidiary of MERCK Kommanditgesellschaft auf Aktien.
STEMCELL Technologies Canada Inc.
39.76
-
International Stem Cell Corporation (OTCPK:ISCO) 2007 Form 10KSB
Business Description: STEMCELL Technologies Canada Inc. develops cell culture media, cell separation systems, instruments, and other reagents to support research in the fields of immunology, hematology, neuroscience, mesenchymal stem cell, stem cell, and epithelial cell biology. It offers antibodies, buffers and solutions, cell culture media and supplements, cell dyes and detection assay kits, cell isolation products, cell storage media, cultureware and general supplies, cytokines, density gradient media, ELISAs, instruments and software, laboratory equipment, matrices and substrates, primary and cultured cells, small molecules, standardization tools, and tissue and cell culture dissociation reagents. The company also provides contract assay services, custom solutions, product and scientific support, and standardization tools. It offers tools for research on immune cells, embryonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neural stem cells, intestinal epithelial cells, mammary epithelial cells, airway epithelial cells, prostate epithelial cells, pancreatic cells, and endothelial cells. The company’s products are available online and through a distributor network. STEMCELL Technologies Canada Inc. was formerly known as STEMCELL Technologies, Inc. The company was founded in 1993 and is based in Vancouver, Canada with locations in North America, Europe, Asia, and Oceania.
Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN)
634.01
Jun-30-2023
Lannett Company, Inc. 2019 Form 10-K
Business Description: Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Syneos Health, Inc.
5,418.97
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.
Thermo Fisher Scientific Inc. (NYSE:TMO)
43,524.00
Jul-01-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX)
9,505.00
Jun-30-2023
Lonza Group AG (SWX:LONN) - Form 
Business Description: Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company’s pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
WuXi AppTec Co., Ltd. (SHSE:603259)
5,531.23
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.
WuXi PharmaTech (Cayman) Inc.
778.47
Sep-30-2015
Dr. Reddy's Laboratories Limited (BSE:500124) 2022 Form 20-F
Business Description: Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical, genomics, bioinformatics, research reagent production, and clinical services; services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products, as well as production of cell therapies. The Manufacturing Services segment provides manufacturing services, including development of manufacturing processes; and the production of advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products, and in commercial products, as well as the production of biologic products. The company sells its products to pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and non-profit organizations. Wuxi PharmaTech (Cayman) Inc. has a strategic partnership with Gilead Sciences Inc. to conduct analytical and stability studies of small-molecule new chemical entities; and strategic collaboration with Eli Lilly and Company to develop, manufacture, and commercialize a novel small molecule. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is headquartered in Shanghai, China. As of December 10, 2015, WuXi PharmaTech (Cayman) Inc. was taken private. Wuxi PharmaTech (Cayman) Inc. operates as a subsidiary of New WuXi Life Science Limited.
*denotes proprietary relationship